MESOTHELIOMA-BINDING ANTIBODIES - THROMBOMODULIN, OV-632 AND HBME-1 AND THEIR USE IN THE DIAGNOSIS OF MALIGNANT MESOTHELIOMA

Citation
Rl. Attanoos et al., MESOTHELIOMA-BINDING ANTIBODIES - THROMBOMODULIN, OV-632 AND HBME-1 AND THEIR USE IN THE DIAGNOSIS OF MALIGNANT MESOTHELIOMA, Histopathology, 29(3), 1996, pp. 209-215
Citations number
27
Categorie Soggetti
Cell Biology",Pathology
Journal title
ISSN journal
03090167
Volume
29
Issue
3
Year of publication
1996
Pages
209 - 215
Database
ISI
SICI code
0309-0167(1996)29:3<209:MA-TOA>2.0.ZU;2-N
Abstract
The aim of this study was to examine the expression of three putative mesothelioma-binding antibodies, thrombomodulin, OV 632 and HBME-1 in 42 malignant mesotheliomas (27 pleural and 15 peritoneal) and 32 pulmo nary adenocarcinomas. Evaluation of their use in differentiating betwe en the mesotheliomas and pulmonary adenocarcinomas was assessed. Throm bomodulin was expressed by 22 of 42 (52%) mesotheliomas but was seen i n eight of 12 pure epithelial-type mesotheliomas of the pleura and in all four papillary epithelial peritoneal mesotheliomas, For pure epith elial mesotheliomas thrombomodulin was 75% sensitive, Only two of 32 p ulmonary adenocarcinomas were immunoreactive yielding a 94% specificit y for thrombomodulin, In comparison, OV 632 and HBME-1 showed 67% and 62% antibody sensitivity, respectively, for malignant mesothelioma but this was accompanied by low specificity (OV 632, 37%; HBME-1, 28%), B oth OV 632 and HBME-1 are considered unsuitable for use in differentia ting between mesotheliomas and pulmonary adenocarcinomas. We advocate the use of thrombomodulin as a mesothelioma-binding antibody in the st andard panel of antibodies used in the evaluation of malignant mesothe lioma.